Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats. A transmission electron microscopic study of capillaries in the cerebellar cortex

Experimental and Toxicologic Pathology

Volumn 48, Issue 1, 1996, Pages 65-75

  Sobaniec Lotowska, Maria E ^a   Sobaniec, Wojciech ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Blood brain barrier; Capillaries; Cerebellar cortex; Encephalopathy; Neuroglial cells; Sodium valproate; Valproate

Indexed keywords

VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN CORTEX; BRAIN DISEASE; CONTROLLED STUDY; INTRAGASTRIC DRUG ADMINISTRATION; LIVER INJURY; MALE; NONHUMAN; RAT; ULTRASTRUCTURE;

EID: 0030040295     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(96)80094-7     Document Type: Article

References (54)

1. ARDINGER HH, ATKIN JF, BLACKSTON RD, et al.: Verification of the fetal valproate syndrome phenotype. Amer J Med Gen 1988; 29: 171-185.
2. BAUER J, ELGER CE: Intoxication und Enzephalopathien unter Valproinsäuretherapie. In: KRÄMER G, LAUB M (eds.): Valproinsäure. Springer Verlag Berlin - Heidelberg - New York 1992, pp. 3-23.
3. CHAPMAN A, KEANE PE, MELDRUM BS, et al.: Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982; 19: 315-359.
4. COLLINS RM Jr, ZIELKE HR, WOODY RC: Valproate increases glutaminase and decreases glutamine synthetase activities in primary cultures of rat astrocytes. J Neurochem 1994; 62: 1137-1143.
5. CORNFORD EM, DIEP CP, PARDRIDGE WM: Blood-brain barrier transport of valproic acid. J Neurochem 1985; 44: 1541-1550.
6. CORNFORD EM, OLDENDORF WH: Epilepsy and the blood-brain barrier. Adv Neurology 1986; 44: 787-812.
7. CRAMER JA, MATTSON RH, BENNET DM, et al.: Variable free and total valproic acid concentrations in sole and multiple-drug therapy. In: LEVY RH, PITLICK WH, EICHELBAUM M (eds.): Metabolism of antiepileptic drugs. Raven Press New York 1984, pp. 105-114.
8. DAM M: The number of Purkinje cells after diphenylhydantoin intoxication in monkeys. Epilepsia 1970; 11: 199-206.
9. DAVIS R, PETERS DH, MCTAVISH D: Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332-372.
10. DEL CERRO MP, SNIDER RS: Studies on Dilantin intoxication. I. Ultrastructural analogies with the lipoidoses. Neurology 1967; 17: 452-466.
11. DREIFUSS FE, LANGER DH, MOLINE KA, et al.: Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989; 39: 201-207.
12. EHLERS K, STURJE H, MERKER HJ, et al.: Valproic acid-induced spina bifida: a mouse model. Teratology 1992; 45: 145-154.
13. GRAF R, GOSSRAU R, MERKER HJ: Enzyme cytochemistry combined with electron microscopy pharmacokinetics, and clinical chemistry for the evaluation of the effects of steady-state valproic acid concentrations on the mouse. Histochemistry 1985; 83: 347-358.
14. JONES GL, MATSUO F, BARINGER JR: Valproic acid-associated encephalopathy. West J med 1990; 153: 199-202.
15. KARKOS J: The influence of antiepileptic drugs on the morphologic picture of the cerebellum in rats. Neuropat Pol 1973; 11: 429-439.
16. KHERA KS: Valproic acid-induced placental and teratogenic effects in rats. Teratology 1992; 45: 603-610.
17. LENN NJ, ELLIS WG, WASHBURN ER, et al.: Fatal hepatocerebral syndrome in siblings discordant for exposure to valproate. Epilepsia 1990; 31: 578-583.
18. LÖSCHER W: Valproic acid. In: Antiepileptic drugs. Handbook of experimental pharmacology. (FREY HH, JANZ D, eds.) Springer, Berlin - Heidelberg - New York - Tokyo 1985; vol. 74, pp. 507-536.
19. LOSCHER W: Pharmakodynamische Wirkungen und biochemische Wirkungsmechanismen. In: KRÄMER G, LAUB M (eds.): Valproinsäure. Springer Berlin - Heidelberg 1992, PP. 3-23.
20. LOSCHER W: Effects of the antiepileptic drug valproate on metabolism and function of in-hibitory and excitatory amino acids in the brain. Neurochem Res 1993; 18: 485-502.
21. LÖSCHER W, ESENWEIN H: Pharmakinetics of sodium valproate in dog and mouse. Arzneimittel Forsch 1978; 8: 782-787.
22. LÖSCHER W, NAU H, WAHNSCHAFFE U, et al.: Effects of valproate and E-2-en valproate on functional and morphological parameters of rat liver. Epilepsy Res 1993; 15: 113-131.
23. LÜCKE A, MAYER T, ALTRUP U, et al.: Simultaneous and continuous measurement of free con-centration of valproate in blood and extracellular space of rat cerebral cortex. Epilepsia 1994; 35: 922-926.
24. MAJKOWSKI J: Valproic acid in antiepileptic therapy (in Polish). Terapia i Leki 1992; 20: 256-263.
25. MAJKOWSKA-WIERZBICKA J: Experimental global cerebral ischemia in rats. I. Ultrastructural changes in cerebral cortex in the postischemic period. Neuropat Pol 1989; 27: 97-114.
26. MCELROY S, KECK PE Jr, POPE HG Jr.: Sodium valoproate: Its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16-24.
27. MOSSAKOWSKI MJ, GAJKOWSKA B: Influence of indomethacin on the ultrastructural pathology of the brain following temporary ischemia in Mongolian gerbils. Neuropat Pol 1984; 22: 347-365.
28. NAU M, MERKER HJ, BRENDEL K: Disposition, embryotoxicity. and teratogenicity of valproic acid in the mouse as related to man. In: LEVY RH, PITLICK WH, EICHELBAUM M (eds.): Metabolism of antiepileptic drugs. Raven Press New York, 1984.
29. PERLMAN BJ, GOLDSTEIN DB: Membrane-disordering potency and anticonvulsant action of valproic acid and other short-chain acids. Molec Pharmacol 1984; 26: 83-89.
30. PERLMAN BJ, GOLDSTEIN DB: Genetic influences on the central nervous system depressant and membrane-disordering actions of ethanol and sodium valproate. Mol Pharmacol 1984; 26: 547-552.
31. RANGEL RJ, WARNER JJ, WIDLER BJ: Valproic acid encephalopathy. J Epilepsy 1988; 1: 197-202.
32. ROCHEL M, EHRENTHAL W: Haematological side effects of valproic acid. In: J. OXLEY J, JAND D, MEINAR-DI H (eds.): Antiepileptic therapy: chronic toxicity of antiepileptic drugs. Raven Press New York, 1983, pp. 101-105.
33. RUMBACH L, MORESCAUX C, WARTER JM, et al.: Die nephrogene, durch Valproinsäure induzierte Hyperammonämie und ihre Beziehung zu den Mitochondrien. In: KRÄMER G, LAUB M (eds.): Valproinsäure. Springer Berlin - Heidelberg - New York 1992, pp. 237-240.
34. SCHEFFNER D, KÖNIG ST: Hepatotoxische Nebenwirkungen von Valproinsäure: Allgemeine Klinische Gesichtspunkte. In: KRÄMER G, LAUB MC (eds.): Valproinsäure. Springer Berlin - Heidelberg - New York 1992, pp. 266-270.
35. SCHÖNDIENST M, WOLF P: Zur Möglichkeit neurotoxischer Spätwirkungen durch Valproinsäure. In: KRÄMER G, LAUB MC (eds.): Valproinsäure. Springer Berlin - Heidelberg - New York 1992, pp. 259-265.
36. SIEMES H, SPOHR HL, MICHAEL TH, et al.: Therapy on infatile spasms with valproate: results of a prospective study. Epilepsia 1988; 29: 553-560.
37. SOBANIEC W: Assessement of undesirable action of sodium valproate in children treatment chronically due to epilepsy. Neurosciences 1991; 17: 281-288.
38. SOBANIEC W, JANKOWICZ E, CZERWIŃSKA-CIECHAN K: Detailed monitoring of valproic acid and phenobarbital in the treatment of epilepsy in children (in Polish). Neur Neurochir Pol 1988; 12: 413-420.
39. SOBANIEC W, JANKOWICZ E, SOBANIEC-LOTOWSKA M: The effect of valproic acid on the morphology of the rat cerebellum and brain stem. Neuropat Pol 1989; 27: 137-150.
40. SOBANIEC W, SOBANIEC-LOTOWSKA M: The effects of sodium valproate and its metabolites (5-OH-VPA and 4-OH-VPA) on the electroconvulsions in rats. Mat Med Pol 1994; 26: 29-32.
41. SOBANIEC-LOTOWSKA M: Hepatic encephalopathy evoked by long-term administration of sodium valproic (VPA). Ultrastructure of hepatocyte, capillaries and neuroglial cells in dentate nucleus of cerebellum. Folk Symposium No 79. Portal Hypertension, June 17-19, Freiburg/Breisgau 1994a; 30 (Abstr.)
42. SOBANIEC-LOTOWSKA M: Ultrastructure of capillaries and neuroglial cells in the cerebellar cortex in rats given chronically sodium valproate. Eur J Pharmaceutical Sci 1994 b; 2: 164.
43. SOBANIEC-LOTOWSKA M, SOBANIEC W: Effect of chronically administration sodium valproate on the morphology of the rat brain hemispheres. Neuropat Pol 1993 a; 31: 153-162.
44. SOBANIEC-LOTOWSKA M, SOBANIEC W: Long-term sodium valproate induced encephalopathy. Pathology Res Pract 1993 b; (Suppl. 814), 189.
45. SOBANIEC-LOTOWSKA M, SOBANIEC W: Hepatocyte ultrastructure, certain enzyme parameters and blood serum ammonia in rats given chronically and acutely sodium valproate (VPA). Falk Symposium No 75 Cholestatic Liver Diseases, April 22-23, 1994, Maastricht 1994 a; 2 (Abstr.).
46. SOBANIEC-LOTOWSKA M, SOBANIEC W: Studies on the rat liver morphology during chronic and acute administration of sodium valproate. Falk Symposium No 79. Portal Hypertension, June 17-19, 1994 Freiburg/Breisgau 1994b; 12 (Abstr.).
47. SOBANIEC-LOTOWSKA M, SOBANIEC W, KULAK W: Rat liver pathomorphology during prolonged sodium valproate administration. Mat Med Pol 1993; 85: 9-12.
48. STEPHENS JR, LEVY RH: Effects of valproate and citrulline on ammonium-induced encephalopathy. Epilepsia 1994; 35: 164-171.
49. SUZUKI J: Sequential changes in cerebral ischemia. Histological study. In: SUZUKI J (ed.): Treatment of cerebral infarction. Experimental and clinical study. Springer Wien - New York 1987, pp. 23-53.
50. TARTARA A, MANNI R: Sodium valproate "encephalopathy". Report of three cases with generalised epilepsy. Ital J Neurol Sci 1985; 6: 93-95.
51. UNKELBACH ST: Pankreas-spezifische Nebenwirkungen unter Valproinsäure. In: KRÄMER G, LAUB MC (eds.): Valproinsäure. Springer Berlin - Heidelberg - New York 1992, pp. 241-251.
52. VOICULESCU V, HATEGAN D, MANOLE E, et al.: The cerebral content of excitatory and inhibitory amino acids in rats following with drawal of antiepileptic drugs. J Neurol Psychiatry 1994; 32: 3-7.
53. WIESER HG: Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res 1991; 9: 154-159.
54. ZACCARA G, PAGANINI M, CAMPOSTRINI R, et al.: Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases. Eur Neurol 1984; 23: 104-112.